Table 1.
Patient baseline characteristics at the time of study entry before and after propensity score matching
| Characteristicsa | Before Matching | After Matching | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| DEB-TACE+LEN (n=54) | DEB-TACE+SOR (n=199) | P value | DEB-TACE+LEN (n=50) | DEB-TACE+SOR (n=100) | P value | |
| Age (y) | 54 (50-62) | 51 (43-60) | 0.017 | 54 (49-61) | 54 (49-63) | 0.863 |
| Sex | 0.497 | 0.171 | ||||
| Male | 50 (92.6%) | 189 (95.0%) | 46 (92.0%) | 97 (97.0%) | ||
| Female | 4 (7.4%) | 10 (5.0%) | 4 (8.0%) | 3 (3.0%) | ||
| HBV | 0.043 | 0.171 | ||||
| Absence | 6 (11.1%) | 8 (4.0%) | 46 (92.0%) | 97 (97.0%) | ||
| Presence | 48 (88.9%) | 191 (96.0%) | 4 (8.0%) | 3 (3.0%) | ||
| Cirrhosis | 0.784 | 1.000 | ||||
| Absence | 14 (25.9%) | 48 (24.1%) | 12 (24.0%) | 24 (24.0%) | ||
| Presence | 40 (74.1%) | 151 (75.9%) | 38 (76.0%) | 76 (76.0%) | ||
| ECOG score | 0.095 | 0.144 | ||||
| 0 | 39 (72.2%) | 164 (82.4%) | 37 (74.0%) | 84 (84.0%) | ||
| 1 | 15 (27.8%) | 35 (17.6%) | 13 (26.0%) | 16 (16.0%) | ||
| AFP (ng/ml) | 1329 (10-9471) | 3170 (234-39513) | 0.033 | 1329 (18-10462) | 264 (28-4234) | 0.164 |
| ≤200 | 23 (42.6%) | 46 (23.1%) | 0.004 | 21 (42.0%) | 45 (45.0%) | 0.727 |
| >200 | 31 (57.4%) | 153 (76.9%) | 29 (58.0%) | 55 (55.0%) | ||
| Child-Pugh class | 0.476 | 0.757 | ||||
| A | 44 (81.5%) | 170 (85.4%) | 41 (82.0%) | 84 (84.0%) | ||
| B | 10 (18.5%) | 29 (14.6%) | 9 (18.0%) | 16 (16.0%) | ||
| Intrahepatic tumors number | 0.095 | 0.581 | ||||
| ≤3 | 12 (22.2%) | 26 (13.1%) | 10 (20.0%) | 24 (24.0%) | ||
| >3 | 42 (77.8%) | 173 (86.9%) | 40 (40.0%) | 76 (76.0%) | ||
| Tumor sizeb (cm) | 8.7 (4.6-12.1) | 10.0 (6.7-12.6) | 0.498 | 8.7 (4.6-12.1) | 9.0 (5.6-11.5) | 0.658 |
| ≤5 | 14 (25.9%) | 30 (15.1%) | 0.062 | 13 (26.0%) | 19 (19.0%) | 0.324 |
| <5 | 40 (74.1%) | 169 (84.9%) | 37 (74.0%) | 81 (81.0%) | ||
| PVTT | <0.001 | 0.210 | ||||
| Absence | 17 (31.5%) | 19 (9.5%) | 14 (28.0%) | 19 (19.0%) | ||
| Presence | 37 (68.5%) | 180 (90.5%) | 36 (72.0%) | 81 (81.0%) | ||
| Extrahepatic metastasis | 0.003 | 0.298 | ||||
| Absence | 24 (44.4%) | 133 (66.8%) | 23 (46.0%) | 55 (55.0%) | ||
| Presence | 30 (55.6%) | 66 (33.2%) | 27 (54.0%) | 45 (45.0%) | ||
a
Median with interquartile range is shown for quantitative variables, whereas counts with proportions are shown for categorical variables.
b
Tumor size, size of the largest tumor.
AFP, alpha-fetoprotein; HBV, hepatitis B virus; PVTT, portal vein tumor thrombus.